GYRE compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

GYREGyre Therapeutics, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

GYREGyre Therapeutics, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only GYRE 4

—Jiangsu Wangao Pharmaceuticalsunlistedsupplier

—Nanjing Healthnice Pharmaceutical Technologyunlistedsupplier

—WuXi STAunlistedsupplier

—GNIunlistedsupplier

Shared 0

No shared counterparties.

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

25 more · LLY chain ›

GYREGyre Therapeutics, Inc.

4.02▼−9.47%· post 4.00

Mkt cap$447.2MRevenue$29MQ2 FY26Revenue$120MFY25

LLYELI Lilly & Co

1,371.32▼−3.29%· post 1,363.77

ClosedNov 5 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 5 '26

GYREGyre Therapeutics, Inc.

LLYELI Lilly & Co

4.02▼−9.47%post 4.00

Price

1,371.32▼−3.29%post 1,363.77

$447.2M

Mkt cap

$1.2T

Q2 FY26$29M

Revenue

$24.4BQ3 FY26

FY25$120M

Revenue

$65.2BFY25

GYRE4.02▼−9.47%vsLLY1,371.32▼−3.29%ClosedNov 5 '26